ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "outcomes and rheumatoid arthritis (RA)"

  • Abstract Number: 1520 • 2016 ACR/ARHP Annual Meeting

    RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year

    Susan M. Goodman1, Susan J. Bartlett2, Ryan Cummings3, Kathleen Andersen3, Edward F. DiCarlo4, Mark P. Figgie5, Laura T. Donlin6, Dana E. Orange7 and Vivian P. Bykerk8, 1Medicine, Hospital for Special Surgery, New York, NY, 2Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 3Hospital for Special Surgery, New York, NY, 4Laboratory Medicine, Hospital for Special Surgery, New York, NY, 5Orthopaedics, Hospital for Special Surgery, New York, NY, 6Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Divison of Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose:   Post-op flares are frequent for RA patients after total hip (THA) and total knee arthroplasty (TKA), when medications are discontinued to mitigate infection…
  • Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting

    Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis

    Neil Accortt1, Jennifer Schenfeld2,3, Eunice Chang4, Elya Papoyan4 and Michael S. Broder4, 1Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, 2Docs Global, Inc, North Wales, PA, 3Amgen Inc., Thousand Oaks, CA, 4Partnership for Health Analytic Research, LLC, Beverly Hills, CA

    Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…
  • Abstract Number: 2468 • 2016 ACR/ARHP Annual Meeting

    Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis

    Nashla Barroso1, Thasia G Woodworth2, Francis Guillemin3, Daniel E. Furst4, Jenny Brook5, Suzanne Kafaja6, David Elashoff5, Bruno Fautrel7 and Veena Ranganath8, 1Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Leading Edge Clinical Research, Stuart, FL, 3CHRU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, 5Medicine, David Geffen School of Medicine, Los Angeles, CA, 6Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 7Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 8Cumberland Valley Rheumatology, P.C., Chambersburg, PA

    Background/Purpose: Due to the lack of consensus of the definition of a rheumatoid arthritis (RA) flare, the French “FLARE” (FLare Assessment in RA) instrument was…
  • Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting

    Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission –  1-Year Results of a Guideline-Directed Longitudinal Cohort Study

    Cecilie Heegaard Brahe1, Simon Krabbe2, Mikkel Østergaard3, Henrik Rogind4, Hanne Slott Jensen3, Annette Hansen5, Jesper Nørregaard6, Søren Jacobsen7, Lene Terslev8, Tuan K. Huynh9, Dorte Vendelbo Jensen5, Natalia Manilo10, Karsten Heller Asmussen11, Per Brown-Frandsen7, Mikael Boesen12, Zoreh Rastiemadabadi13, Daniel Glinatsi14, Lone Morsel-Carlsen15, Jakob M. Møller16, Niels Steen Krogh17 and Merete Lund Hetland3,18, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 2Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 4Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 5DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 7Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 8Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, 9Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, 10The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, 11Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, 12Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark, 13Department of Radiology, Frederiksberg Hospital, Frederiksberg, Denmark, 14Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, 15Department of Radiology, Rigshospitalet, Copenhagen, Denmark, 16Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, 17Zitelab, Frederiksberg, Denmark, 18Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark

    Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…
  • Abstract Number: 467 • 2015 ACR/ARHP Annual Meeting

    Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values

    In Je Kim1, Hyesook Park2, Sang-Cheol Bae3 and Jisoo Lee4, 1Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, 2Dep of Preventive medicine, Ewha Womans University School of medicine, Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 4Internal Medicine, Ewha Womans Univeristy School of Medicine, Seoul, South Korea

    Background/Purpose: Despite high clinical disease activity measured by joint counts and global assessments, some patients with active rheumatoid arthritis (RA) have normal acute-phase reactant (APR)…
  • Abstract Number: 469 • 2015 ACR/ARHP Annual Meeting

    Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters

    Virginia Pascual-Ramos1 and Irazú Contreras-Yáñez2, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: The window of opportunity concept states that there are superior clinical responses and the potential for remission, when patients with rheumatoid arthritis (RA) are…
  • Abstract Number: 575 • 2015 ACR/ARHP Annual Meeting

    Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients

    Toshihisa Kojima1, Nobunori Takahashi1, Koji Funahashi1, Shuji Asai2, Toki Takemoto2, Nobuyuki Asai3, Tatsuo Watanabe2, Naoki Ishiguro4 and TBCR Study Group, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Nagoya University Hospital, Nagoya, Japan, 3Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 4Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: : Currently, there is no clarity regarding which biologic to switch to when patients fail to respond to TNF inhibitors (TNFis). Detailed information for…
  • Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting

    Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort

    Claire I. Daien1, Jeremie Sellam2, Nathalie Rincheval3, Bruno Fautrel4, Alain Saraux5, Francis Berenbaum6, Jacques Morel1, Jean-Pierre Daures7 and Bernard Combe8, 1Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, 2Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, 3Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, 4Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, 5Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 6Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, 7Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, 8Rheumatology, Hopital Lapeyronie, Montpellier, France

    Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
  • Abstract Number: 1577 • 2015 ACR/ARHP Annual Meeting

    Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate

    Melanie Rohr1, James R. O'Dell1, Abhijeet Danve2, Harlan Sayles1, Geoffrey M. Thiele3, Jeffrey Payne4 and Ted R. Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Research Services 151, Omaha VA Medical Center, Omaha, NE, 4College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, 5Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis (RA) outcomes have improved substantially due to the development of new drug therapies, but also due to emphasis on early aggressive MTX…
  • Abstract Number: 2590 • 2015 ACR/ARHP Annual Meeting

    Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis

    Brian Coburn1, Geoffrey M. Thiele1, Michael J. Duryee2, Fang Yu3, Harlan Sayles4, Jeremy Sokolove5, WH Robinson6, Alan Erickson7, Mary Brophy8, James R. O'Dell1 and Ted R. Mikuls1, 1Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Public Health, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Stanford University, Palo Alto, CA, 6VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, 8VA Boston Heathcare System, Boston, MA

    Background/Purpose: Anti-citrullinated protein antibody (ACPA) positivity is associated with more rapid radiographic progression in rheumatoid arthritis (RA). A majority of prior studies, however, have assessed…
  • Abstract Number: 2671 • 2015 ACR/ARHP Annual Meeting

    Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis

    Abhijeet Danve1, Harlan Sayles2, Ted R. Mikuls3 and James R. O'Dell2, 1Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Methotrexate (MTX) is routinely used as the first-line drug for rheumatoid arthritis (RA). About 1 in 3 RA patients achieve excellent RA control with…
  • Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting

    Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study

    Rossella Reggia1, Ilaria Cavazzana1, Angela Tincani2 and Franco Franceschini1, 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy

    Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for  active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
  • Abstract Number: 2401 • 2014 ACR/ARHP Annual Meeting

    Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy?

    Liam O'Neil1, Carol A. Hitchon2, David B. Robinson3, Navjot Dhindsa1, Hani El-Gabalawy3 and Christine A. Peschken4, 1Medicine, University of Manitoba, Winnipeg, MB, Canada, 2Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 3Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, 4University of Manitoba, Canada, Winnipeg, MB, Canada

    Background/Purpose: Severe disease and poor outcomes have been described in First Nation (FN) patients with Rheumatoid Arthritis (RA). We examined the contributions of interrupted and…
  • Abstract Number: 2390 • 2014 ACR/ARHP Annual Meeting

    Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis

    Chandana Keshavamurthy1, Kevin Kuriakose2, Deepak Chandra2, Aneet Kaur2, Horace Spencer2 and Nasim A. Khan3, 1Division of Rheumatology, University of Arkansas for Medical Sciences, Little Rock, AR, 2University of Arkansas for Medical Sciences, Little Rock, AR, 3Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR

    Background/Purpose Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy is recommended to improve rheumatoid arthritis (RA) outcomes. The aim of this study was to determine…
  • Abstract Number: 1060 • 2014 ACR/ARHP Annual Meeting

    Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study

    H Cawston1, F Bourhis1, T Le2 and E Alemao3, 1OptumInsight, Nanterre, France, 2Bristol-Myers Squibb, Hopewell, NJ, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Musculoskeletal surgeries and procedures substantially improve the quality of life of patients with RA, but represent an important burden in terms of medical costs.…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology